Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant

Paused · Phase 2 · Has a placebo group

Conditions studied: Post Traumatic Stress Disorder

In brief

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Intervention C - Daridorexant will assess the safety and efficacy of daridorexant in participants with PTSD. Please see NCT05422612 for information on the S-21-02 Master Protocol.

Key facts

Study ID
NCT05948540
Run by
Global Coalition for Adaptive Research
People needed
200
Starts
2023-11-02
Expected to finish
2029-07-01
Last updated by the study team
2026-06-30

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.